Memantine combinations and use

Abstract

A pharmaceutical combination of memantine and a non-anticholinergic antiemetic agent for the treatment of hypocholinergic disorders in further combination with high doses of donepezil and with solifenacin, and kits comprising said combination. A pharmaceutical combination of memantine and solifenacin for the treatment of hypocholinergic disorders, including Alzheimer type dementia, in further combination with high doses of donepezil, and kits comprising said combination.

What is claimed is: 
     
         1 .- 5 . (canceled) 
     
     
         6 . A method for the treatment of a hypocholinergic disorder, which comprises treating a patient in need of said treatment with an effective dose of a N-methyl-D-aspartate receptor antagonist Component (a) selected from the group consisting of memantine and pharmaceutical acceptable salts thereof and with an effective amount of a naAEA Component (b), in further combination with
 (c) donepezil or a pharmaceutically acceptable salt thereof, in an amount that is equivalent to from 10 mg to 92 mg of donepezil hydrochloride and;   (d) solifenacin or a pharmaceutically acceptable salt thereof, in an amount that is equivalent to from 10 mg to 30 mg of solifenacin succinate.   
     
     
         7 . The method of  claim 6 , wherein said effective amount of memantine or a pharmaceutically acceptable salt thereof Component (a), is a daily dose that is equivalent to from 5 mg to 30 mg of memantine hydrochloride. 
     
     
         8 . The method of  claim 6 , wherein
 said Component (a) is a pharmaceutical composition in dosage unit form comprising said memantine or pharmaceutically acceptable salt thereof in an amount that is equivalent to from 5 mg to 30 mg of memantine hydrochloride, in admixture with a pharmaceutical carrier or vehicle;   said Component (b) is a pharmaceutical composition in dosage unit form comprising a naAEA selected from the group consisting of alosetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in alosetron) of from 0.25 mg to 6 mg; azasetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in azasetron) of from 5 mg to 60 mg; dolasetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in dolasetron) of from 25 mg to 600 mg; granisetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in granisetron) of from 0.5 mg to 6 mg; ondansetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in ondansetron) of from 2 mg to 64 mg; palonosetron and pharmaceutically acceptable salts and solvated thereof, in an amount (in palonosetron) of from 0.25 mg to 3 mg; ramosetron and pharmaceutically acceptable salts and solvates thereof, in an amount (in ramosetron) of from 0.0125 mg to 0.3 mg; tropisetron and pharmaceutically acceptable salts and solvates thereof, in an amount of from 2.5 mg to 30 mg; domperidone and pharmaceutically acceptable salts and solvates thereof, in an amount (in domperidone) of from 5 mg to 60 mg; haloperidol, in an amount of from 0.5 mg to 60 mg; chlorpromazine and pharmaceutically acceptable salts and solvates thereof, in an amount (in chlorpromazine) of from 12.5 mg to 600 mg; prochlorperazine and pharmaceutically acceptable salts and solvates thereof, in an amount (in prochlorperazine) of from 2.5 mg to 30 mg; metoclopramide and pharmaceutically acceptable salts and solvates thereof, in an amount (in metoclopramide) of from 5 mg to 60 mg; bromopride and pharmaceutically acceptable salts and solvates thereof, in an amount (in bromopride) of from 5 mg to 60 mg; clebopride and pharmaceutically acceptable salts and solvates thereof, in an amount (in clebopride) of from 0.25 mg to 3 mg; levosulpiride, in an amount of from 12.5 mg to 600 mg; alizapride and pharmaceutically acceptable salts thereof, in an amount (in alizapride) of from 25 mg to 300 mg; trimethobenzamide and pharmaceutically acceptable salts thereof, in an amount (in trimethobenzamide) of from 50 mg to 600 mg; meclizine (also called meclozine) and pharmaceutically acceptable salts and solvates thereof, in an amount (in meclizine) of from 6.25 mg to 300 mg; promethazine and pharmaceutically acceptable salts and solvates thereof, in an amount (in promethazine) of from 12.5 mg to 150 mg; dronabinol in an amount of from 1.25 mg to 60 mg; nabilone, in an amount of from 0.5 mg to 6 mg; aprepitant, in an amount of from 20 mg to 750 mg; netupitant, in an amount of from 150 mg to 1800 mg; rolapitant, in an amount of from 30 mg to 360 mg; and casopitant, in an amount of from 25 mg to 300 mg, in admixture with a pharmaceutical carrier or vehicle;   said Component (c) is a pharmaceutical composition in dosage unit form comprising donepezil or pharmaceutically acceptable salt thereof in an amount that is equivalent to from 20 mg to 92 mg of donepezil hydrochloride, in admixture with a pharmaceutical carrier; and   said Component (d) is a pharmaceutical composition in dosage unit form comprising solifenacin or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition comprising said solifenacin or pharmaceutically acceptable salt thereof in an amount that is equivalent to from 10 mg to 30 mg of solifenacin succinate, in admixture with a pharmaceutical or vehicle.   
     
     
         9 . The method of  claim 8 , wherein
 said Component (a) is a pharmaceutical composition comprising said memantine hydrochloride in an amount of from 7 mg to 28 mg, in admixture with a pharmaceutical carrier in an ER formulation; and   said Components (c) and (d) are in a fixed-dose (c/d) combination consisting of a pharmaceutical composition in dosage unit form comprising   
       (c) donepezil hydrochloride, in an amount of from 10 mg to 92 mg; and 
       (d) solifenacin succinate, in a pharmaceutical composition comprising said solifenacin succinate in an amount of from 10 mg to 30 mg,
 in admixture with a pharmaceutical carrier or vehicle, in an IR-formulation. 
 
     
     
         10 . The method of  claim 9  wherein, in said fixed-dose combination (c/d) said Component (c) is donepezil hydrochloride, in an amount of from 10 mg to 50 mg; and said Component (d) is solifenacin succinate, in an amount of 15 mg. 
     
     
         11 .- 26 . (canceled)